IMMP

Immutep Limited ADR

3.06

Oct 30 • 3:59 PM ET -0.27 (-8.11%)

3.09

Aftermarket • 4:15 PM ET +0.03 (0.98%)

Healthcare Biotechnology Australia Nano NASD

Oct 29, 8:05 AMImmutep pivots to registration-directed efti trials in HNSCC CPS<1 and neoadjuvant soft tissue sarcoma

Peers: AGEN CUE BYSI CADL CMPX CRVS XNCR REGN IOVA BMY

| Held by: IBB

Scroll to Statements

Index	-
Market Cap	22.55M
Enterprise Value	-24.44M
Income	-53.59M
Sales	10.03M
Book/sh	5.79
Cash/sh	6.47
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	-
IPO	Apr 17, 2012

P/E	-
Forward P/E	-
PEG	-
P/S	2.25
P/B	0.53
P/C	0.47
P/FCF	-
EV/EBITDA	-
EV/Sales	-2.44
Quick Ratio	5.69
Current Ratio	5.69
Debt/Eq	0.02
LT Debt/Eq	0.01
Option/Short	No / Yes

EPS (ttm)	-7.28
EPS next Y	-1.63
EPS next Q	-1.45
EPS this Y	75.42%
EPS next Y	14.31%
EPS next 5Y	41.66%
EPS past 3/5Y	-7.01% 0.02%
Sales past 3/5Y	- -
EPS Y/Y TTM	-33.93%
Sales Y/Y TTM	-
EPS Q/Q	3.43%
Sales Q/Q	-
Earnings	Aug 30 AMC
EPS/Sales Surpr.	-548.84% -15.17%

Insider Own	0.84%
Insider Trans	0.00%
Inst Own	1.13%
Inst Trans	-96.53%
ROA	-66.76%
ROE	-78.38%
ROIC	-124.19%
Gross Margin	85.21%
Oper. Margin	-586.33%
Profit Margin	-534.13%
SMA20	-11.57%
SMA50	-41.78%
SMA200	-82.10%
Trades

Shs Outstand	7.37M
Shs Float	7.31M
Short Float	0.46%
Short Ratio	2.09
Short Interest	0.03M
52W High	70.60 -95.67%
52W Low	3.04 0.66%
Volatility	9.49% 7.14%
ATR (14)	0.29
RSI (14)	24.09
Beta	2.28
Rel Volume	0.66
Avg Volume	16.02K
Volume	10,594

Perf Week	-4.38%
Perf Month	-32.60%
Perf Quarter	-59.78%
Perf Half Y	-64.92%
Perf YTD	-94.65%
Perf Year	-92.03%
Perf 3Y	-91.64%
Perf 5Y	-96.43%
Perf 10Y	-94.60%
Recom	1.75
Target Price	19.66
Prev Close	3.33
Price	3.06
Change %	-8.11%

Consensus

Buy

Avg. Price Target

$19.66

Implied Upside

+542.5%

Analysts6incl. previous ratings

Rating Distribution3 Buy · 3 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Mar 13, 2026	Downgrade	RRobert W. Baird	Outperform → Neutral	$1	-67.3%
Mar 13, 2026	Downgrade	MMaxim Group	Buy → Hold
Mar 13, 2026	Downgrade	CCitizens	Mkt Outperform → Mkt Perform
Feb 17, 2026	Initiated	CCitizens	Mkt Outperform	$6	+96.1%
May 17, 2024	Initiated	CCapitalOne	Overweight	$10	+226.8%
Aug 03, 2023	Initiated	RRobert W. Baird	Outperform	$7	+128.8%
Aug 03, 2021	Initiated	LLadenburg Thalmann	Buy	$8.30	+171.2%
Jul 16, 2021	Resumed	MMaxim Group	Buy	$8	+161.4%
Sep 28, 2018	Initiated	BB. Riley FBR	Buy	$7.75	+153.3%
Feb 15, 2018	Reiterated	MMaxim Group	Buy	$7 → $5	+63.4%

Oct-29-26 08:00AM	Immutep Quarterly Activities Report Q1 FY27 (GlobeNewswire)
Oct-28-26 08:00AM	Immutep Receives A$2.16 million French R&D Tax Incentive (GlobeNewswire) +5.40%
Oct-23-26 08:00AM	Immutep Announces Presentation of Quality of Life Data from EFTISARC-NEO Phase II Trial at ESMO 2026 (GlobeNewswire)
Oct-19-26 08:00AM	Immutep Announces Late-Breaking Abstract on IMP761 Accepted for Poster Presentation at ACR Convergence 2026 (GlobeNewswire)
Oct-14-26 08:00AM	Immutep and Monash University Secure Further ARC Linkage Projects Funding for LAG-3 Research (GlobeNewswire) -5.32%
08:00AM	Loading…
Oct-13-26 08:00AM	Immutep Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire)
Sep-30-26 08:00AM	Immutep Receives ~A$0.86 Million R&D Tax Incentive (GlobeNewswire)
Sep-21-26 08:00AM	Change to American Depositary Share Ratio (GlobeNewswire)
Sep-11-26 08:00AM	Immutep Outlines Focused Development Strategy for Eftilagimod Alfa ("efti") (GlobeNewswire) +14.83%
Jul-30-26 08:00AM	Immutep Quarterly Activities Report Q4 FY26 (GlobeNewswire)
Jul-24-26 08:00AM	Immutep Announces Abstract Accepted for Presentation at the European Society for Medical Oncology (ESMO) Congress 2026 (GlobeNewswire)
Jul-14-26 08:00AM	Immutep Secures Fourth United States Patent for Eftilagimod Alfa in Combination with a PD-1 Pathway Inhibitor (GlobeNewswire)
Jul-13-26 08:00AM	Immutep Provides Clinical Update in 1st line NSCLC: Positive Mature Overall Survival Data from INSIGHT-003 and Update from TACTI-004 (GlobeNewswire) +7.52%
Jun-25-26 04:52AM	Immutep Limited Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - IMMP (PR Newswire) +5.44%
Jun-15-26 02:34AM	Immutep Limited Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - IMMP (PR Newswire)
02:54AM	Loading…
Jun-11-26 02:54AM	Immutep Limited Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - IMMP (PR Newswire)
Jun-04-26 08:00AM	Immutep to Present Positive Interim Phase I Data for IMP761, a First-in-Class LAG-3 Agonist Antibody, at EULAR 2026 (GlobeNewswire)
Jun-03-26 03:02AM	Immutep Limited Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - IMMP (PR Newswire)
May-28-26 08:00AM	Systemic immune activation with eftilagimod alfa associated with statistically significant increased overall survival in late-stage cancer patients (GlobeNewswire)
Apr-30-26 08:00AM	Immutep Receives Nasdaq Notice of Bid Price Deficiency (GlobeNewswire)
08:00AM	Immutep Quarterly Activities Report Q3 FY26 (GlobeNewswire)
Apr-22-26 08:00AM	Immutep Announces Abstract Accepted for Presentation at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting (GlobeNewswire)
Apr-15-26 08:00AM	Immutep Receives FDA Orphan Drug Designation for Eftilagimod Alfa in Soft Tissue Sarcoma (GlobeNewswire) +72.81%
Mar-30-26 12:14AM	Lost Money on Immutep Limited (IMMP)? Possible Fraud - Contact Levi & Korsinsky Today (Newsfile)
Mar-19-26 08:00AM	Immutep Reports Progress from Phase I Study of LAG-3 Agonist for Autoimmune Diseases (GlobeNewswire)
Mar-13-26 03:02PM	Immuteps LAG-3 hopes take a hit on Phase III NSCLC termination (Clinical Trials Arena) -82.44%
09:39AM	Adobe downgraded, Nio upgraded: Wall Street's top analyst calls (The Fly)
08:00AM	TACTI-004 Phase III Study in First Line NSCLC to be discontinued following Futility Analysis (GlobeNewswire)
06:17AM	Evotec, Vistagen lay off staff; Immutep shares collapse on study failure (BioPharma Dive)
Feb-06-26 08:00AM	Immutep Achieves 50% Enrolment in Global TACTI-004 (KEYNOTE-F91) Phase III Trial in 1L NSCLC (GlobeNewswire)
08:00AM	Loading…
Jan-29-26 08:00AM	Immutep Quarterly Activities Report Q2 FY26 (GlobeNewswire)
Jan-21-26 12:14PM	Dr. Reddy's Laboratories Q3 Earnings Call Highlights (MarketBeat)
Dec-22-25 08:00AM	Immutep Announces Positive Update on IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune Diseases, from Phase I Study (GlobeNewswire)
Dec-16-25 08:00AM	Immutep Announces Strong Operational Progress in Global TACTI-004 (KEYNOTE-F91) Phase III and Enrolment Continues at Robust Pace (GlobeNewswire)
Dec-15-25 12:35PM	Immutep (IMMP) Scores Win After Announcing Deal With Indian Firm (Insider Monkey) -5.43%
Dec-10-25 02:13PM	Immutep Limited (IMMP): Firm Reports Positive Data from Trials (Insider Monkey) +11.11%
Dec-08-25 08:00AM	Immutep and Dr. Reddy's enters into Strategic Collaboration for Commercialisation of an Innovative Oncology Drug, Eftilagimod Alfa (GlobeNewswire) +26.11%
Dec-02-25 08:00AM	Immutep to Present New Data from AIPAC-003 Phase II at the 2025 San Antonio Breast Cancer Symposium (GlobeNewswire) -7.07%
Nov-13-25 08:00AM	Translational Data and Significant Pathologic Response Rates from EFTISARC-NEO Phase II Highlighted in Oral Presentation at CTOS 2025 (GlobeNewswire)
Nov-03-25 08:00AM	Immutep Receives A$4.6 million R&D Tax Incentive from French Government (GlobeNewswire)
Oct-29-25 08:00AM	Immutep Quarterly Activities Report Q1 FY26 (GlobeNewswire)
Oct-20-25 08:01AM	Primary Endpoint Met in EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma and Data Presented at ESMO Congress 2025 (GlobeNewswire)
08:00AM	Two Posters at ESMO Congress 2025 Highlight Immutep's Focus on Changing Treatment Landscape in First Line Non-Small Cell Lung Cancer (GlobeNewswire)
Oct-13-25 08:00AM	Immutep Announces Successful Completion of FDA Project Optimus Requirements (GlobeNewswire)
Oct-09-25 08:00AM	Immutep Announces Update for TACTI-004 (KEYNOTE-F91) Phase III Trial in First Line Non-Small Cell Lung Cancer (GlobeNewswire)
Sep-22-25 08:00AM	Immutep Announces Research Collaboration with the George Washington University Cancer Center to Evaluate Neoadjuvant Efti (GlobeNewswire) +6.21%
Sep-08-25 08:00AM	Immutep Announces Data from EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma Accepted for Oral Presentation at CTOS 2025 (GlobeNewswire)
Aug-17-25 01:52AM	Immutep Limited (IMMP) Receives Positive FDA Feedback on Future Clinical Development of Eftilagimod Alfa (Insider Monkey)
Jul-30-25 08:00AM	Immutep Quarterly Activities Report Q4 FY25 (GlobeNewswire)
Jul-29-25 08:00AM	Immutep to Present Pivotal TACTI-004 Trial in Progress Poster at the 2025 World Conference on Lung Cancer (GlobeNewswire)
Jul-28-25 08:00AM	Immutep Announces Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2025 (GlobeNewswire)
Jun-29-25 01:28PM	Immutep (IMMP) Announces Positive Initial Efficacy Data and Continued Favourable Safety Data (Insider Monkey)
Jun-23-25 08:00AM	Immutep Announces Positive Update from Phase I Study of IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune Diseases (GlobeNewswire) -5.00%
May-27-25 08:00AM	Immutep's Efti with Radiotherapy & KEYTRUDA (pembrolizumab) Meets Primary Endpoint in Phase II for Soft Tissue Sarcoma (GlobeNewswire)
May-15-25 08:00AM	Immutep's Efti with KEYTRUDA (pembrolizumab) & Chemotherapy Achieves High Response Rates in First-Line Non-Small Cell Lung Cancer (GlobeNewswire) +8.20%
Apr-29-25 08:00AM	Immutep Quarterly Activities Report Q3 FY25 (GlobeNewswire)
Apr-02-25 08:00AM	Immutep to Participate in Upcoming Investor Conferences (GlobeNewswire) -5.65%
Mar-31-25 11:50AM	Immutep: A Small Company With A Pipeline Resembling Big Pharma (Seeking Alpha) -5.38%
Mar-25-25 08:00AM	First Patient Dosed in Immutep's TACTI-004 Phase III Trial in First Line Non-Small Cell Lung Cancer (GlobeNewswire)
Mar-20-25 08:00AM	Immutep to Present Pivotal TACTI-004 Trial in Progress Poster at the European Lung Cancer Congress 2025 (GlobeNewswire)
Jan-31-25 08:00AM	Immutep Quarterly Activities Report Q2 FY25 (GlobeNewswire)
Jan-22-25 08:00AM	Patient Enrolment Completed for EFTISARC-NEO Phase II Trial (GlobeNewswire)
Jan-06-25 08:00AM	Patient Enrolment Completed for INSIGHT-003 (GlobeNewswire)
Dec-17-24 08:00AM	Immutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761 (GlobeNewswire)
Dec-16-24 08:00AM	Immutep and Monash University Announce First Publication Detailing How Human LAG-3 Binds to MHC Class II (GlobeNewswire)
Dec-13-24 08:20AM	Immutep announces results from Cohort B of TACTI-003 trial (TipRanks)
Dec-12-24 08:15AM	Immutep Reports Promising New Data in Head and Neck Cancer at ESMO Immuno-Oncology 2024 (GlobeNewswire) -5.30%
Dec-10-24 08:00AM	Immutep Announces Initiation of TACTI-004 Phase III Trial in First Line Non-Small Cell Lung Cancer (GlobeNewswire)
Nov-14-24 08:15AM	Immutep's Efti Shows Excellent Survival Data from INSIGHT-003 Trial in Non-Small Cell Lung Cancer (GlobeNewswire) +11.76%
08:00AM	Positive Data from Phase II Trial in Soft Tissue Sarcoma Presented at CTOS 2024 Annual Meeting (GlobeNewswire)
Oct-29-24 08:00AM	Immutep Quarterly Activities Report Q1 FY25 (GlobeNewswire)
Oct-28-24 08:00AM	Immutep to Present New Phase IIb Data in PD-L1 Negative (CPS (GlobeNewswire)
Oct-17-24 08:00AM	Immutep Announces First-in-Human Phase I Study of IMP761 Progresses to Dose Escalation Portion of Trial (GlobeNewswire)
Oct-10-24 08:00AM	Immutep to Participate in the 2024 Maxim Healthcare Virtual Summit (GlobeNewswire)
Oct-04-24 06:12AM	Immutep concludes participant enrolment in Phase II breast cancer trial (Clinical Trials Arena)
Oct-03-24 08:00AM	Immutep Completes Patient Enrolment in Randomised Phase II of AIPAC-003 Trial in Metastatic Breast Cancer (GlobeNewswire)
Sep-24-24 08:00AM	Immutep Receives A$3.6 million R&D Tax Incentive from French Government (GlobeNewswire)
Sep-18-24 08:00AM	New Data to be Presented from EFTISARC-NEO Phase II Evaluating Novel Triple Combination including Immutep's Efti in Soft Tissue Sarcoma (GlobeNewswire)
Sep-16-24 08:00AM	Immutep's Efti in Combination with MSD's KEYTRUDA Leads to Positive Efficacy with Favourable Safety in First Line Head and Neck Cancer (GlobeNewswire) -12.50%
Aug-20-24 08:00AM	Immutep Announces Late-Breaking Abstract in Head & Neck Cancer Selected for Oral Presentation at ESMO Congress 2024 (GlobeNewswire)
Aug-14-24 08:00AM	Immutep Announces First Participant Dosed in Phase I Study of IMP761, a First in Class Agonist LAG-3 Antibody (GlobeNewswire) +8.54%
Aug-07-24 08:00AM	Immutep to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jul-31-24 08:00AM	Immutep Quarterly Activities Report Q4 FY24 (GlobeNewswire)
Jul-22-24 08:00AM	Immutep Announces Successful Meeting with FDA on Phase III Design in Non-Small Cell Lung Cancer (GlobeNewswire)
Jul-17-24 08:00AM	Immutep Receives Regulatory Clearance for Phase I Study of First-in-Class LAG-3 Agonist Antibody Designed to Treat Autoimmune Diseases (GlobeNewswire)
Jul-15-24 08:39AM	Immutep (IMMP) Up as Combo Therapy Meets Carcinoma Study Goals (Zacks) -11.69%
Jul-12-24 09:15AM	Immutep tries to regain pep as cancer subgroup data show path forward with a long list of caveats (FierceBiotech.com) +14.93%
07:41AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace)
Jul-11-24 06:40PM	Immutep Reports Positive Results in First Line Head and Neck Squamous Cell Carcinoma Patients with Negative PD-L1 Expression (GlobeNewswire)
Jul-03-24 08:00AM	Immutep Announces Details for Oral Presentation at ESMO Virtual Plenary Session and Webcast to Discuss Clinical Results (GlobeNewswire) +5.32%
Jun-27-24 07:34AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday (InvestorPlace) -32.49%
Jun-25-24 08:00AM	Immutep Signs Exclusive License Agreement with Cardiff University for Next Generation Anti-LAG-3 Molecules for Cancer (GlobeNewswire)
Jun-05-24 06:00AM	Immutep successfully completes institutional placement and institutional component of entitlement offer (GlobeNewswire) -12.08%
Jun-02-24 08:38PM	Immutep Announces Clinical Collaboration with MSD to Evaluate Efti in Combination with KEYTRUDA (pembrolizumab) in Pivotal Phase III Trial (GlobeNewswire)
May-15-24 08:00AM	Immutep Presents Data from Safety Lead-in Phase of AIPAC-003 at ESMO Breast 2024 (GlobeNewswire)
May-02-24 08:00AM	Positive Initial Clinical Data Reported from Immutep's Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma (GlobeNewswire)
Apr-29-24 08:00AM	Immutep Quarterly Activities Report Q3 FY24 (GlobeNewswire)
Apr-24-24 08:00AM	Immutep Announces Positive Preliminary Topline Results from TACTI-003 Cohort B (GlobeNewswire)
Apr-18-24 08:00AM	Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761 (GlobeNewswire)
Apr-17-24 08:00AM	Immutep Receives Positive Feedback from the Spanish Medicines Agency for Upcoming TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer (GlobeNewswire)

Show Previous News

Immutep Ltd. is a clinical stage biotechnology company, which engages in the development of LAG-3 related immunotherapeutic products for cancer and autoimmune diseases. Its products include eftilagimod alfa (IMP321), IMP761, leramilimab (IMP701), and GSK'781 (IMP731). The company was founded on May 21, 1987 and is headquartered in Sydney, Australia.

CEOMr. Marc Voigt

COOMs. Deanne Miller LLB

Ph.D.Dr. Frederic Triebel M.D.

MSc.Mr. Christian Mueller BBA

Ph.D.Dr. Stephan Winckels M.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

IMMP

Immutep Limited ADR

Upgrade your Finviz experience